Stuart Naylor - MeiraGTx Holdings Chief Development Officer
| MGTX Stock | USD 5.93 0.01 0.17% |
Executive
Dr. Stuart Naylor, Ph.D. is Chief Development Officer of the Company. From April 2015 to April 2016, Dr. Naylor was Chief Executive Officer of Athena Vision Limited, a biotechnology company. From June 2013 to April 2015, Dr. Naylor served as managing director of Coltivare Ltd., a healthcare consulting company. From 2008 to 2013, Dr. Naylor was Executive Director and Chief Scientific Officer of Oxford BioMedica plc, a gene therapy company. Prior to joining Oxford BioMedica plc, Dr. Naylor focused on translational cancer research at the Institute of Cancer Research in London since 2019.
| Age | 61 |
| Tenure | 5 years |
| Address | 450 East 29th Street, New York, NY, United States, 10016 |
| Phone | 646 860 7985 |
| Web | https://meiragtx.com |
Stuart Naylor Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stuart Naylor against MeiraGTx Holdings stock is an integral part of due diligence when investing in MeiraGTx Holdings. Stuart Naylor insider activity provides valuable insight into whether MeiraGTx Holdings is net buyers or sellers over its current business cycle. Note, MeiraGTx Holdings insiders must abide by specific rules, including filing SEC forms every time they buy or sell MeiraGTx Holdings'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stuart Naylor over six months ago Exercise or conversion by Stuart Naylor of 23750 shares of MeiraGTx Holdings subject to Rule 16b-3 | ||
Stuart Naylor over six months ago Exercise or conversion by Stuart Naylor of 75000 shares of MeiraGTx Holdings subject to Rule 16b-3 | ||
Stuart Naylor over a year ago Acquisition by Stuart Naylor of 100000 shares of MeiraGTx Holdings subject to Rule 16b-3 |
MeiraGTx Holdings Management Efficiency
The company has return on total asset (ROA) of (0.3666) % which means that it has lost $0.3666 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9151) %, meaning that it created substantial loss on money invested by shareholders. MeiraGTx Holdings' management efficiency ratios could be used to measure how well MeiraGTx Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, MeiraGTx Holdings' Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 1.5 M in 2024, whereas Total Assets are likely to drop slightly above 247.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MPH DO | Kronos Bio | 59 | |
| Eileen Sawyer | Uniqure NV | N/A | |
| MD JD | Rocket Pharmaceuticals | N/A | |
| MS CPA | Erasca Inc | 57 | |
| David Krempa | Eton Pharmaceuticals | 35 | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
| Mayo Pujols | Rocket Pharmaceuticals | 55 | |
| Bryan JD | Eledon Pharmaceuticals | 44 | |
| Yung MD | Keros Therapeutics | 48 | |
| Esq JD | Erasca Inc | 52 | |
| Monique Silva | AnaptysBio | N/A | |
| Jim Flaherty | Rhythm Pharmaceuticals | N/A | |
| Jennifer Lee | Rhythm Pharmaceuticals | 48 | |
| Mark Mossler | C4 Therapeutics | 51 | |
| Marc MD | Edgewise Therapeutics | 67 | |
| Robin Wagner | Keros Therapeutics | N/A | |
| Stu Dorman | Ideaya Biosciences | N/A | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| John JD | Edgewise Therapeutics | 60 | |
| Carla Poulson | Uniqure NV | N/A | |
Management Performance
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.37 |
MeiraGTx Holdings PLC Leadership Team
Elected by the shareholders, the MeiraGTx Holdings' board of directors comprises two types of representatives: MeiraGTx Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MeiraGTx. The board's role is to monitor MeiraGTx Holdings' management team and ensure that shareholders' interests are well served. MeiraGTx Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MeiraGTx Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexandria Forbes, President CEO, Director | ||
| Robert MD, Chief Officer | ||
| Tim Randall, Senior Controls | ||
| Christine Sheehy, Senior Integration | ||
| Richard BA, COO CFO | ||
| Joel Brooks, VP Fin | ||
| Alastair Leighton, Senior Chain | ||
| Stuart Naylor, Chief Development Officer | ||
| Robert JD, General Secretary | ||
| Michel MD, Head Ophthalmology |
MeiraGTx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MeiraGTx Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (162.80) % | ||||
| Current Valuation | 427.31 M | ||||
| Shares Outstanding | 78.15 M | ||||
| Shares Owned By Insiders | 24.24 % | ||||
| Shares Owned By Institutions | 55.12 % | ||||
| Number Of Shares Shorted | 1.66 M | ||||
| Price To Earning | (1.93) X | ||||
| Price To Book | 4.84 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MeiraGTx Stock Analysis
When running MeiraGTx Holdings' price analysis, check to measure MeiraGTx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MeiraGTx Holdings is operating at the current time. Most of MeiraGTx Holdings' value examination focuses on studying past and present price action to predict the probability of MeiraGTx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MeiraGTx Holdings' price. Additionally, you may evaluate how the addition of MeiraGTx Holdings to your portfolios can decrease your overall portfolio volatility.